BenevolentAl Therapeutics Pipeline and Triage
Given the limitations of current available topical therapies, there is a
large unmet need for an efficacious and safe alternative topical
therapy for the treatment of patients with Atopic Dermatitis
TREATMENT FLOW
Atopic Dermatitis Treatment Paradigm
Mild
Steroid Treatment
Moderate
Calcineurin inhibitors
Eucrisa/PDE4
inhibitors
Topical JAKS
BEN-2293 (PanTrk)
PanTrk positioning
Severe
Key Insights:
•
Topical Corticosteroids (with increasing potency) - Poor side effect profile
and concern of use by patients
Calcineurin inhibitors (pimecrolimus or tacrolimus) - Poor side effect
profile with associated black box warning
PDE4 inhibitors - Issues with site application irritancy
Immunosuppressants (azathioprine, ciclosporin and methotrexate) - Poor
side effect profile
Topical JAKS - ruxolitinib recently approved in the US, not yet approved in
EU, but approval issued with a black box warning
Anti IL13/IL4 mAbs (Dupilumab) - high cost treatment only indicated in
moderate-severe.
Need for better treatment solutions
Current
Future
Source: GlobalData and Company internal drug programmes
Immuno-
suppressants
Dupilumab
Other anti-IL13/IL4
mAbs
BEN-2293 (PanTrk) - Combined solution addressing itch, inflammation
and potential disease modifying effects, together with an improved safety
profile and no irritancy on application
Potential to displace ineffective 2nd line treatment for chronic use
in adults and paediatrics
Potential use in a subset of 1st line patients where rapid itch
resolution is key
Potential for use in the severe patient population as an adjunct
treatment option
○
Oral JAKS
O
Benevolent 69
ΑΙView entire presentation